AstraZeneca's CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell lymphoma ...

“Our oral presentation at ASH this year with data from the FELIX trial demonstrates that obe-cel treatment produces a high ... cell therapies, announces a poster presentation at the 2024 ...